Cas:178419-47-1 (5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one manufacturer & supplier

Chemical Name:(5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one

CAS.NO:178419-47-1

Synonyms:(3S)-spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one;(S)-spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin]-2′-one;spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin]-2′-one;(S)-(-)-spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidine-2′-one]

Molecular Formula:C₉H₁₄N₂O₂

Molecular Weight:182.22000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:41.57000

Exact Mass:182.10600

LogP:0.45730

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (3S)-spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-(-)-spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidine-2′-one] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3S)-spiro[1-azabicyclo[2.2.2]octan-3,5′-oxazolidin]-2′-one Use and application,spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin]-2′-one technical grade,usp/ep/jp grade.

Related News: From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. (5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one manufacturer From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. (5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one supplier Without disclosing or confirming the number of vaccine doses, the FDA said in a news release that it had authorized two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated. (5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one vendor ��Ultimately, this is a public health decision,�� she said, adding that the restrictions were precautionary measures to keep the country virus-free and contain the worldwide outbreak. (5S)-spiro[1,3-oxazolidine-5,3′-1-azabicyclo[2.2.2]octane]-2-one factory In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company.